Presse23
Posted - 3 days ago
$EQ yikes getting to delisting territory
VinWeezel
Posted - 1 week ago
$EQ https://www.businesswire.com/news/home/20241113027002/en/ still got some cash, keeping the hope alive 💲
Rounderssss4
Posted - 1 week ago
$GNPX $TCBP watch $EQ had news earlier this morning , oversold like $TCBP holding both
Presse23
Posted - 2 weeks ago
$EQ delisting coming soon
Skeetz99
Posted - 2 weeks ago
$EQ Itolizumab clinical response rates Equillium is currently testing itolizumab in a US phase 1b/2 trial (EQUATE) in patients with high-risk aGVHD, who typically have low response to steroids, the current standard of care. Granted both Orphan and Fast Track status for aGVHD by the US Food and Drug Administration, if approved, itolizumab will fill a need for a first-line therapy for aGVHD. Positive interim data from the EQUATE trial showed an 80% overall response rate (ORR) across the first three dose cohorts and complete responses (CR) in 7 of 8 patients responding. In the second two dose cohorts, the ORR was 100%
Presse23
Posted - 2 weeks ago
$EQ things have gone south quickly!!!!
RealErnFranklin
Posted - 2 weeks ago
$SRM folks cant stop talking about it and a few other gemz. Dem da plays manz, dont over think it. If I wanna tell the Mrs. I made nothing again, noone’s opposing that
$LAES looks bottom getting solid
$eq hope ya sold 1.4 , take ur profits. It is hard, to not believe. Very.
$CVRX smokin chart. 19.42 clear $tcs everyone bought a container. Damn. Now what. Yes, 2 container
RavesRamirez
Posted - 3 weeks ago
@Presse23 it's not a huge market, but it never was. The market didn't change since the deal with Ono was announcing and they thought it was worth investing in. Not a huge investment of course, but big enough to have a significant impact on a small company like this.
There'll be other companies who still think so and they won't need to take the risk of a failed Phase 2/3.
That should give $EQ the time and money they need to continue developing their pipeline.
We're talking about a company relatively small company, it doesn't need to be a big market to get it to 200m or 400m market cap. Ofc it doesn't need much to bring it down either, but it still seems worth the risk.
Presse23
Posted - 3 weeks ago
$EQ if we know bankruptcy is coming why drag it out so long. 80 cent stock headed to 10 cents any day now, but we'll suffer through releases and calls on nada as they have nada now without Ono
RavesRamirez
Posted - 3 weeks ago
$EQ my guess is that the exchange rate between Yen and Dollar has much to do with the decision - since they agreed to the deal the yen sank roughly 30% - and maybe the not all that great numbers of Ono.
To my (limited) knowledge the data was good and the market for the drug didn't change much since then.
My hope is they can find a new partner quicky - maybe even get a better deal, a lot of the development has ben done, so the risk for any investor is less then a few years ago.
What are your thoughts/opinions?
BioInvCA
Posted - 3 weeks ago
$EQ The pipeline is garbage. The lead asset probably works, but it will need to have great data to find a new home. The hand-back will make others skeptical of the data is just decent.
LewisDaKat
Posted - 10/31/24
$EQ $EQ Nhttps://marketwirenews.com/news-releases/equillium-maintains-rights-to-itolizumab-following-o-5386776584052367.html ews out Equillium Maintains Rights to Itolizumab Following Ono Partnership
bearishbull69
Posted - 10/31/24
$EQ Great buying opp here imo. Solid data with catalysts in Q1 25 right around the corner
sogenerous
Posted - 10/31/24
$EQ decided to close this spec play went from+ 6k gain to -7.4k about a 13k swing. In hindsight the fact some obvious signs that partnership would end with payment not having hit yesterday. Win some and lose some. Upside was still pretty asymmetric I put it around 5-10:1 R/R. Can still come back as other catalysts but deciding to move on and not waste more time with it
Skeetz99
Posted - 10/31/24
$EQ Smart money is buying heading into two data releases in Q1 25. Don’t look in the rear view mirror; Ono’s decision will not set this company back.
Whyasking
Posted - 10/31/24
$EQ Sorry, but EQ's actions are very amateurish. If they don't need a partner, why did they look for one? Many investors have relied on it.
VrtcIl
Posted - 10/31/24
Let's get that 2 on $EQ. However, make sure to keep stop set and always protect your downside. Never blindly keep on holding, let the market dictate your decisions. Price: 1.14 Float: 18.8M Short Float: 1.2 % 💰 Dollar Volume: 34.2K ℹ️ USA | Biotechnology
trader2360
Posted - 10/31/24
$EQ , $LUXH, let's do it.
CloudGuy
Posted - 10/31/24
$EQ from the call, safety and tolerability were not an issue at the Oct 15th data review for the 150+ trial patients. CRR data was provided as well.
Presse23
Posted - 10/31/24
$EQ Such a weird dynamic. On call they are saying they are happy to be back in fully control of the drug. Then why were they willing to give the rights away in the first place. I guess you can look at it as Ono did a lot of the heavy financial lifting with $90 million, but playing up how thrilled they are about being on their own again makes you wonder.
trader2360
Posted - 10/31/24
$EQ is good to go. Get in and make some money.
Wisenheimer
Posted - 10/31/24
$EQ ono saw the data and ran as simple as that.
Wisenheimer
Posted - 10/31/24
$EQ warned everyone yesterday and last month - a true partner doesn’t wait till the last day. This is headed sub .30 imho
Luckytoo8
Posted - 10/31/24
$EQ charts are in very solid bullish territory
Luckytoo8
Posted - 10/31/24
$EQ Great news...Nasdaq compliance,,,oct 31 st....https://www.sec.gov/ix?doc=/Archives/edgar/data/0001746466/000119312524248138/d787967d8k.htm
SEVENXStheGOAT
Posted - 10/31/24
$EQ Ono Pharmaceutical makes strategic business decision to allow Itolizumab option to expire.
Equillium evaluating accelerating completion of Phase 3 EQUATOR study in aGVHD to Q1'25
Phase 2 ulcerative colitis study recently completed; topline data expected Q1'25
Presse23
Posted - 10/31/24
$EQ I hope they at least say something about what went wrong with Ono
